In vitro evaluation of aerosols delivered via the nasal route

Respiratory Care

Volumn 60, Issue 7, 2015, Pages 1015-1025

  El Taoum, Katia K ^a   Xi, Jinxiang ^b   Kim, Jong Wong ^b   Berlinski, Ariel ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL MICHIGAN UNIVERSITY   (United States)

^c ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

Aerosol delivery; Airway model; Face mask; Lung dose; Nasal interface; Nebulizer; Tidal volume

Indexed keywords

SALBUTAMOL SULFATE; AEROSOL; BRONCHODILATING AGENT; SALBUTAMOL;

AEROSOL; ARTICLE; BREATHING MECHANICS; BREATHING PATTERN; CHILD; DRUG DELIVERY SYSTEM; FACE MASK; HUMAN; INFANT; INTRANASAL DRUG ADMINISTRATION; LUNG MODEL; MATERIALS TESTING; NEBULIZER KIT; PRESCHOOL CHILD; SPECTROPHOTOMETRY; TIDAL VOLUME; ADMINISTRATION AND DOSAGE; EQUIPMENT DESIGN; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MASK; NEBULIZER; NEWBORN; PHYSIOLOGY; PROCEDURES; THEORETICAL MODEL;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; CHILD, PRESCHOOL; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; IN VITRO TECHNIQUES; INFANT; INFANT, NEWBORN; LUNG; MASKS; MODELS, THEORETICAL; NEBULIZERS AND VAPORIZERS; TIDAL VOLUME;

EID: 84944720433     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.03606     Document Type: Article

References (34)

1. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-689.
2. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165(9):847-856.
3. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, Mc- Namara S, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307(21):2269-2277.
4. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group. J Pediatr 1998;133(4):486-491.
5. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118(4):1774-1793.
6. Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: an update meta-analysis. Pediatr Neonatol 2014;55(6):431-438
7. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. http:// www.ginasthma.org/. Accessed June 15, 2014.
8. Expert Panel Report 3 (EPR3): guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007.
9. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37(6):1308-1331.
10. Skaria S, Smaldone G. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010; 23(3):173-180.
11. Lin HL, Restrepo RD, Gardenhire DS, Rau JL. Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care 2007;52(8):1021-1026.
12. Harris KW, Smaldone GC. Facial and ocular deposition of nebulized budesonide: effect of face mask design. Chest 2008;133(2):482-488.
13. Janssens HM, van der Wiel EC, Verbraak AF, de Jongste JC, Merkus PJ, Tiddens HA. Aerosol therapy and the fighting toddler: is administration during sleep an alternative? J Aerosol Med 2003;16(4):395-400.
14. Chavez A, McCracken A, Berlinski A. Effect of face mask static dead volume, respiratory rate and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010;45(3):224-229.
15. Xi J, Berlinski A, Zhou Y, Greenberg B, Ou X. Breathing resistance and ultrafine particle deposition in nasal-laryngeal airways of a newborn, an infant, a child, and an adult. Ann Biomed Eng 2012;40(12): 2579-2595.
16. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, Le Souef PN. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994;7(12):2185-2191.
17. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81(2):163-165.
18. Murakami G, Igarashi T, Adachi Y, Matsuno M, Sawai M, Yoshizumi A, Okada T. Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy 1990; 64(4):383-387.
19. Berlinski A. Effect of dead space and occlusion of mask holes on delivery of nebulized albuterol. Respir Care 2014;59(8):1228-1232.
20. Esposito-Festen JE, Ates B, van Vliet FJ, Verbraak AF, de Jongste JC, Tiddens HA. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. J Aerosol Med 2004;17(1):1-6.
21. Esposito-Festen J, Ijsselstijn H, Hop W, van Vliet F, de Jongste J, Tiddens H. Aerosol therapy by pressured metered-dose inhaler-spacer in sleeping young children: to do or not to do? Chest 2006;130(2): 487-492.
22. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377(9770):1032-1045.
23. Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008;53(6):699-723; discussion 723-725.
24. Bhashyam AR, Wolf MT, Marcinkowski AL, Saville A, Thomas K, Carcillo JA, Corcoran TE. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv 2008;21(2):181-188.
25. Ari A, Harwood R, Sheard M, Dailey P, Fink JB. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol 2011;46(8):795-801.
26. Restrepo RD, Dickson SK, Rau JL, Gardenhire DS. An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing. Respir Care 2006;51(1):56-61.
27. Mansour MM, Smaldone GC. Blow-by as potential therapy for uncooperative children: an in-vitro study. Respir Care 2012;57(12): 2004-2011.
28. Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004;37(5):447-452.
29. Laube BL, Sharpless G, Shermer C, Nasir O, Sullivan V, Powell K. Deposition of albuterol generated by pneumatic nebulizer in the Sophia anatomical infant nose-throat (SAINT) model. Pharm Res 2010;27(8):1722-1729.
30. Tiemersma S, Minocchieri S, van Lingen RA, Nelle M, Devadason SG. Vibrating membrane devices deliver aerosols more efficiently than standard devices: a study in a neonatal upper airway model. J Aerosol Med Pulm Drug Deliv 2013;26(5):280-286.
31. Amirav I, Borojeni AA, Halamish A, Newhouse MT, Golshahi L. Nasal versus oral aerosol delivery to the “lungs” in infants and toddlers. Pediatr Pulmonol 2014 [Epub ahead of print] doi: 10.1002/ ppul.22999.
32. Amirav I, Luder A, Chleechel A, Newhouse MT, Gorenberg M. Lung aerosol deposition in suckling infants. Arch Dis Child 2012; 97(6):497-501.
33. Jauering J, Mitchell J, Berg E, Dennis J, Kreher C, Lamb P, et al. Position paper: recommendation on the adoption of breathing patterns for infants and small children in general. Chapter 2.9. 44. Preparations for nebulization. Pharmeur Sci Notes 2008;(1):31-32.
34. Berlinski A, Willis JR. Albuterol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in vitro model. Respir Care 2013;58(7):1124-1133.